Investors One-year Losses Continue as Northeast Pharmaceutical Group (SZSE:000597) Dips a Further 6.9% This Week, Earnings Continue to Decline
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process
Northeast Pharmaceutical (000597.SZ) plans to pay 1 yuan for every 10 shares in 2023, excluding interest on May 23
Northeast Pharmaceutical (000597.SZ) announced that in 2023, the company plans to distribute cash to all shareholders for every 10 shares...
Investors Holding Back On Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)
With a price-to-earnings (or "P/E") ratio of 20.8x Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) may be sending bullish signals at the moment, given that almost half of all companies in China
Northeast Pharmaceutical's Unit Gets Nod to Produce Azithromycin for Injection
Northeast Pharmaceutical Group's (SHE:000597) unit, Dongyao Group Shenyang Shide Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for the
Northeast Pharmaceutical (000597.SZ): Net profit of 576.33,900 yuan in the first quarter decreased 17.72% year-on-year
Gelonghui, April 26 | Northeast Pharmaceutical (000597.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1.94 billion yuan, down 17.58% year on year; net profit attributable to shareholders of listed companies was 576.339 million yuan, down 17.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 298.409 million yuan, down 32.96% year on year; basic earnings per share were 0.040 yuan
Solid Earnings May Not Tell The Whole Story For Northeast Pharmaceutical Group (SZSE:000597)
The recent earnings posted by Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) were solid, but the stock didn't move as much as we expected. We think this is due to investors looking beyond the
Northeast Pharmaceutical (000597.SZ): Net profit increased 2.34% to 358 million yuan in 2023, plans to pay 10 to 1 yuan
Gelonghui, March 29丨Northeast Pharmaceutical (000597.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 8.243 billion yuan, a year-on-year decrease of 6.42%; net profit attributable to shareholders of listed companies was 358 million yuan, up 2.34% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 262 million yuan, an increase of 131.60% year on year; basic income per share was 0.25 yuan; it plans to distribute a cash dividend of 1 yuan (tax included) to all shareholders for every 10 shares.
Northeast Pharmaceutical Group Co., Ltd.'s (SZSE:000597) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 17% over the past three months, it is easy to disregard Northeast Pharmaceutical Group (SZSE:000597). However, the company's fundamentals look pretty decent, and long-term financ
Northeast Pharmaceutical's Levocarnitine Gets Nod to Enter EU Market
Northeast Pharmaceutical Group (SHE:000597) received the European Pharmacopoeia's Certificate of Suitability for levocarnitine, allowing the product to enter and be marketed in the European Union. The
There Is A Reason Northeast Pharmaceutical Group Co., Ltd.'s (SZSE:000597) Price Is Undemanding
Northeast Pharmaceutical Group Co., Ltd.'s (SZSE:000597) price-to-earnings (or "P/E") ratio of 15.9x might make it look like a strong buy right now compared to the market in China, where around half o
Dongfang Steel Pledge Company, the largest shareholder of Northeast Pharmaceutical (000597.SZ), holds 13.65% of the shares
Northeast Pharmaceutical (000597.SZ) issued an announcement. The company recently received Jiangxi West Steel Co., Ltd., the largest shareholder of the company...
The One-year Underlying Earnings Growth at Northeast Pharmaceutical Group (SZSE:000597) Is Promising, but the Shareholders Are Still in the Red Over That Time
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. Investors in North
Northeast Pharmaceutical's Piracetam Passes Generic Drug Evaluation in China
Northeast Pharmaceutical Group (SHE:000597) said its piracetam bioequivalent passed the quality and efficacy consistency evaluation of generic drugs in China. The regulator also authorized the drugmak
Northeast Pharmaceutical (000597.SZ): Piracetam injection obtained a notice of approval of the drug supplement application
Gelonghui on October 31丨Northeast Pharmaceutical (000597.SZ) announced that recently, Northeast Pharmaceutical Group Co., Ltd. received the “Notice of Approval of Supplemental Drug Applications” for piracetam injections approved and issued by the State Drug Administration. After review, the product passed the generic drug quality and efficacy consistency evaluation. At the same time, the following changes were agreed: 1. Change drug prescriptions and production processes (including batches); 2. Change drug quality standards; 3. Change packaging materials and containers that come into direct contact with drugs; 4. Change expiration dates and storage conditions. Piracetam is a drug for improving brain metabolism and is a cyclic derivative of gamma-aminobutyric acid
Northeast Pharmaceutical (000597.SZ): Net profit of 84.8937 million yuan in the third quarter increased 446.03% year-on-year
Glonghui, Oct. 26 | Northeast Pharmaceutical (000597.SZ) announced its report for the third quarter of 2023. Revenue for the reporting period was 1,888 billion yuan, down 11.72% year on year; net profit attributable to shareholders of listed companies was 84.8937 million yuan, up 446.03% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 87.2798 million yuan, up 172.37% year on year; basic earnings per share were 0.0592 yuan.
Should Weakness in Northeast Pharmaceutical Group Co., Ltd.'s (SZSE:000597) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
With its stock down 4.9% over the past week, it is easy to disregard Northeast Pharmaceutical Group (SZSE:000597). But if you pay close attention, you might find that its key financial indicators lo
Northeast Pharmaceutical to Set Up Joint Venture With Muscat Changming Investments in Oman
Northeast Pharmaceutical Group (SHE:000597) signed an investment framework agreement with Muscat Changming Investments for the establishment of a joint venture pharmaceutical company in Oman. As part
Interpretation of Northeast Pharmaceutical's 2023 Interim Report: Net profit increased by 19.80%, but net cash flow declined by 40.55%
According to the 2023 interim report data of Northeast Pharmaceutical, revenue for the reporting period was 4,506,385,834.60 yuan, an increase of 1.95% compared to 4,420,024,191.33 yuan in the same period last year. This indicates that the company has improved in terms of operations, but the increase has not been significant. Meanwhile, net profit attributable to shareholders of listed companies during the reporting period was 134,886,215.06 yuan, an increase of 19.80% compared to 112,591,389.75 yuan in the same period last year. This indicates that the company's profitability has improved; however, during the reporting period it was attributed to listed company shares
Northeast Pharmaceutical (000597.SZ) released first-half results, net profit of 135 million yuan, an increase of 19.80%
Northeast Pharmaceutical (000597.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Is Northeast Pharmaceutical Group (SZSE:000597) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe
No Data